CTOs on the Move

ONL Therapeutics

www.onltherapeutics.com

 
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

ONL Therapeutics raised $46.9M on 12/22/2020

Similar Companies

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Engage Therapeutics

Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.

Precision IBD

Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.